Piramal Pharma's stock surged 5.5% following a strong Q2 earnings report, with net profit increasing 3.5 times year-on-year to Rs 22.59 crore. The company's CDMO business, which constitutes 59% of total revenue, saw a 24% sales growth to Rs 1,320 crore, driven by rising demand for innovation-driven projects. Additionally, Piramal announced an $80 million expansion plan for its Lexington facility, aimed at enhancing sterile fill-finish capabilities by FY27.